137 related articles for article (PubMed ID: 36335813)
1. An immune-related gene signature for the prognosis of human bladder cancer based on WGCNA.
Cheng J; Zhang S; Fan A; Li Y; Xu P; Huang J; He M; Wang H
Comput Biol Med; 2022 Dec; 151(Pt A):106186. PubMed ID: 36335813
[TBL] [Abstract][Full Text] [Related]
2. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis related genes mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide immunotherapy in bladder cancer.
Zhou L; Xu G; Huang F; Chen W; Zhang J; Tang Y
BMC Med Genomics; 2023 Apr; 16(1):88. PubMed ID: 37118734
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465
[TBL] [Abstract][Full Text] [Related]
6. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
[TBL] [Abstract][Full Text] [Related]
8. Identification of tryptophan metabolism- and immune-related genes signature and prediction of immune infiltration landscape in bladder urothelial carcinoma.
Zhou G; Qin G; Zhang Z; Zhao H; Xue L
Front Immunol; 2023; 14():1283792. PubMed ID: 37954600
[TBL] [Abstract][Full Text] [Related]
9. Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer.
Dong B; Liang J; Li D; Song W; Zhao S; Ma Y; Song J; Zhu M; Yang T
Front Genet; 2021; 12():696912. PubMed ID: 34512722
[No Abstract] [Full Text] [Related]
10. Prediction of Prognosis and Recurrence of Bladder Cancer by ECM-Related Genes.
Zhao H; Chen Z; Fang Y; Su M; Xu Y; Wang Z; Gyamfi MA; Zhao J
J Immunol Res; 2022; 2022():1793005. PubMed ID: 35450397
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
Shi X; Peng X; Chen Y; Shi Z; Yue C; Zuo L; Zhang L; Gao S
Front Immunol; 2023; 14():1326509. PubMed ID: 38130721
[TBL] [Abstract][Full Text] [Related]
12. Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma.
Li H; Zu X; Hu J; Xiao Z; Cai Z; Gao N; Chen J
Front Immunol; 2022; 13():964393. PubMed ID: 36211344
[TBL] [Abstract][Full Text] [Related]
13. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.
Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y
Front Immunol; 2022; 13():965469. PubMed ID: 36090967
[TBL] [Abstract][Full Text] [Related]
14. Construction and experimental validation of a B cell-related gene signature to predict the prognosis and immunotherapeutic sensitivity in bladder cancer.
Zhou R; Zhou J; Muhuitijiang B; Zeng X; Tan W
Aging (Albany NY); 2023 Jun; 15(12):5355-5380. PubMed ID: 37379131
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive analysis of immunogenic cell death and its key gene HSP90AA1 in bladder cancer.
Song Q; Zhou Z; Bai J; Liu N
Clin Transl Oncol; 2023 Aug; 25(8):2587-2606. PubMed ID: 37000291
[TBL] [Abstract][Full Text] [Related]
16. Development and experimental validation of a folate metabolism-related gene signature to predict the prognosis and immunotherapeutic sensitivity in bladder cancer.
Liu X; Chen C; Xu P; Chen B; Xu A; Liu C
Funct Integr Genomics; 2023 Sep; 23(4):291. PubMed ID: 37676513
[TBL] [Abstract][Full Text] [Related]
17. Prediction of immune infiltration and prognosis for patients with urothelial bladder cancer based on the DNA damage repair-related genes signature.
Li T; Jiang N; Bai Y; Liu T; Zhao Z; Xu X; Zhang Y; Wei F; Sun R; Liu S; Li J; Guo H; Yang R
Heliyon; 2023 Mar; 9(3):e13661. PubMed ID: 36873527
[TBL] [Abstract][Full Text] [Related]
18. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
Front Immunol; 2021; 12():725223. PubMed ID: 34484235
[TBL] [Abstract][Full Text] [Related]
19. Identification of a cancer-associated fibroblast signature for predicting prognosis and immunotherapeutic responses in bladder urothelial carcinoma.
Gu Y; Zhuo H
Aging Male; 2023 Dec; 26(1):2233609. PubMed ID: 37428096
[TBL] [Abstract][Full Text] [Related]
20. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
[No Abstract] [Full Text] [Related]
[Next] [New Search]